Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
吡咯替尼联合卡培他滨治疗HER2阳性转移性乳腺癌伴脑转移患者（PERMEATE试验）：一项多中心、单臂、双队列II期试验的总生存期结果
期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2024.102837
Yan, Min; Ouyang, Quchang; Sun, Tao; Niu, Limin; Yang, Jin; Li, Li; Song, Yuhua; Hao, Chunfang; Chen, Zhanhong; Liu, Zhenzhen; Lv, Huimin; Zhang, Mengwei; Liu, Liping; Yang, Xiaohong; Xiao, Huawu; Gao, Zhichao; Li, Xiaorui; Dong, Fangyuan; Zhang, Lingxiao; Dong, Danfeng; Chen, Xiuchun; Qiao, Jianghua; Zhang, Guifang; Zeng, Huiai; Wang, Jing; Sun, Huihui; Feng, Yajing; Chen, Yuting; Xia, Fangzhou
